FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to use of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine or its N-glucuronide metabolite (1), or any of their pharmaceutically acceptable salts for treating or preventing HIV infection or AIDS in a patient for whom ineffectiveness or reduced effectiveness of previous treatment of HIV infection. Invention also relates to other applications of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine or its N-glucuronide metabolite.
(1).
EFFECT: proposed use of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinoline-2-amine or its N-glucuronide metabolite (1) enables reducing a viral load in a patient infected with HIV, with prolonged effect and absence of resistance.
6 cl, 8 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL QUINOLINE DERIVATIVE FOR USE IN TREATING AND PREVENTING VIRAL INFECTIONS | 2016 |
|
RU2723013C2 |
| MICRORNA-124 AS BIOMARKER | 2014 |
|
RU2687366C2 |
| METHOD OF INHIBITING HIV REPLICATION IN CELLS OF MAMMALS AND HUMANS | 2011 |
|
RU2593948C2 |
| CCR5 ANTAGONIST FOR ENHANCING IMMUNORESTORATIVE THERAPY AND TREATMENT OF OPPORTUNISTIC INFECTION IN PATIENTS WITH HIV | 2007 |
|
RU2420284C2 |
| DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
| USE OF BISPHOSPHONATES AS HIV/AIDS ADJUNCTIVE TREATMENT | 2015 |
|
RU2671973C2 |
| TREATMENT AND FUNCTIONAL CURE OF HIV-INFECTION WITH MONOCLONAL ANTIBODIES TO CD4 MEDIATING COMPETITIVE INHIBITION OF HIV ENTRY | 2014 |
|
RU2762315C2 |
| INGENOL DERIVATIVES FOR REACTIVATION OF LATENT HIV VIRUS | 2013 |
|
RU2609512C2 |
| METHOD FOR DETERMINING OPTIMUM CHEMOTHERAPY FOR TREATING HIV-SEROPOSITIVE PATIENTS BASED ON PHENOTYPIC HUMAN HIV STRAINS SENSITIVITY TO DRUGS | 1997 |
|
RU2174014C2 |
| USE OF INACTIVATED INTACT VIRUS OF COMPATIBLE SUBTYPE TO OBTAIN ACELLULAR VACCINE AND METHOD OF TREATING HIV INFECTION | 2005 |
|
RU2396346C2 |
